Gapping up
In reaction to strong earnings/guidance:
- RWLK +18.2%, COLL +11.5%, PCMI +11.1%, EYES +10.8%, BURL +9.7%, OCUL +8.9%, SSI +7.9%, SHLO +7.9%, CMTL +7.7%, CZR +6.4%, IGT +6.3%, CTMX +4.7%, XENE +4.7%, (also collaborative development and license agreement with Teva terminated), WYNN +4.2%, (provides recent operational and financial results -- update following first month since the appointment of Matt Maddox as new CEO), THO +4.2%, WUBA +3.5%, RVLT +3.4%, GNE +3.2%, PGNX +2.5%, REVG +2.4%, HRTG +2.3%, OKTA +2.2%, BKCC +2.2%, CLDX +2%, LB +1%, (March comps +3%, announces new $250 million share repurchase plan) WTTR +0.8%, MTN +0.8%, .
M&A news:
- ESRX +16.5% (to be acquired by Cigna (CI) for approximately $67 bln in cash & stock ($48.75/share in cash, 0.2434/share in stock) )
- BBRG +14.2% ( to be acquired by Spice Private Equity, an affiliate of GP Investments; BBRG's shareholders will receive $4.05/share in cash)
Other news:
- RWLK +18.2% (announces $20 mln strategic investment from Timwell Corporation at $1.25/share)
- WGO +2.3% (following THO results)
- DVN +2.3% (Devon Energy increases quarterly dividend to $0.08/share from $0.06/share; board authorizes a $1.0 bln share-repurchase program of common stock over the next year; enters into an agreement to sell the southern portion of its Barnett Shale position for $553 mln)
- MDRX +2.1% (provides update in response to certain inaccurate information introduced into the market regarding Allscripts' business in Singapore)
- LVS +1.5% (higher with WYNN / CZR)
Analyst comments:
- MCHP +3.1% (upgraded to Buy from Neutral at Goldman)
- WEN +1.9% (upgraded to Buy from Neutral at Longbow)
- BHGE +1.7% (upgraded to Buy from Neutral at UBS)
- PH +0.9% (upgraded to Outperform from Neutral at Robert W. Baird)
- WLL +0.7% (upgraded to Neutral at BofA/Merrill)
![]()